Progress has also been made in terms of identifying sensitive cancer indications and effective drug combinations: in HER2+ breast cancer, HSP90 inhibitors block HER2 signaling and suppress tumor growth as the stability of HER2 protein is dependent on HSP90. Here, ERBB2 is linked to breast cancer.